Purpose: To evaluate polyalkylamide gel (PAIG) use in treating HIV-associated facial lipoatrophy (FLA) 4 years after its injection in an open-label, randomized controlled trial (RCT). Methods: Five patients were treated with PAIG in a pilot study, and 31 patients were subsequently enrolled in the RCT of immediate or delayed (12 weeks later) PAIG injections. Endpoints included proportion of participants with complications; changes in FLA severity score (FLSS); and quality of life (QoL), depression, anxiety, and satisfaction scores. Infections were classifi ed as "confi rmed" if purulent material was extracted and/or an organism cultured. Infections were classifi ed as "possible" if only clinical signs were present without purulent discharge or microbiologic confi rmation. Results: Year 4 results were available for 5 pilot and 27 full-scale study participants. Delayed complications included 5 confi rmed infections (15.6%), 3 possible infections (9.4%), nodules (25%), and bleeding (3%). No signifi cant changes were observed between years 2 to 4 in patient-graded FLSS, QoL, depression, and anxiety scores. Whereas 94% of participants were satisfi ed with their overall treatment, only 69% were satisfi ed with PAIG treatment specifi cally. Conclusion: Even though PAIG treatment was associated with delayed complications including high rates of infection and nodules, most patients were satisfi ed with the treatment.
F
acial lipoatrophy (FLA) remains one of the most distressing complications of antiretroviral therapy (ART) for patients infected with HIV. [1] [2] [3] The iatrogenic depletion in facial fat can be highly stigmatizing for patients, can lead to poor self-esteem and depression, and may subsequently negatively affect ART adherence. [1] [2] [3] [4] Because effective medical therapies for reversing FLA have been lacking, emphasis has been placed on correction of FLA using facial fi llers. [5] [6] [7] The 2 most commonly used facial fi llers for the treatment of HIV-associated FLA are poly-L-lactic acid (PLA) (New-Fill; Biotech Industry SA, Luxembourg) 8, 9 and polyalkylimide gel (PAIG) (BioAlcamid; Polymekon, Biotech Industrie, Milan, Italy). [10] [11] [12] PAIG possesses several properties that may be advantageous relative to other products, including the requirement of only a single course of treatment; PAIG yields results that are permanent, but removal is easy should such need subsequently arise. 13 It is a nonbiodegradable, nonallergenic, nontoxic polymer composed of 96% nonpyrogenic water and 4% polyalkylimide. To date, it has been shown to be safe and effective in the treatment of HIV-associated FLA. 10, 11, 13 We previously reported the week 48 and 96 results of a randomized, open-label study of PAIG for the correction of FLA in 31 HIV-positive patients. 14, 15 The results of the study demonstrated that treatment with PAIG was safe and effective at both time points, resulting in sustained reductions in the severity of FLA and improvements in patient QoL, if purulent material was extracted and/or an organism cultured. Infections were classifi ed as "possible" if only clinical signs were present, including erythema, edema, and pain, without purulent discharge or microbiologic confirmation. In cases where complications were described, additional questions were asked about the timing of their onset relative to the initial injection, peak severity based on a visual analogue scale of 0 to 10, and duration. Additional questions were asked regarding potential precipitating factors and management of the complications. Other outcome measures included the FLA severity scores (FLSS) using the 5-point Carruthers scale and QoL, depression, and anxiety scores using validated surveys. [31] [32] [33] [34] The FLSS is a validated 4-point grading scale of FLA ranging from 1 (mild FLA) to 4 (severe FLA). 31 Grade 0 was used to represent the condition of no FLA. 14 Quality of life and depression were assessed using the Medical Outcomes Study HIV Health Survey (MOS-HIV), the Hospital Anxiety and Depression Scale (HADS), and the slightly modifi ed Dermatology Quality of Life Survey (sDQLS); these have all been validated and previously described. [32] [33] [34] Satisfaction with treatment was assessed by asking patients the following questions: "Overall, how satisfi ed are you with the treatment you received?" (ie, overall treatment) and "Overall, how satisfi ed are you with the Bio-Alcamid injections?" (ie, PAIG treatment specifi cally). For these questions, participants could answer on a 5-point Likert scale that included the following options: very unsatisfi ed, unsatisfi ed, neither unsatisfi ed or satisfi ed, satisfi ed, and very satisfi ed. A fi nal binary question was asked about whether they would recommend treatment with PAIG injections.
Statistical Analysis
Demographics and adverse events were summarized using frequencies and proportions for categorical variables and median and interquartile range (IQR) for continuous variables such as duration and severity. Differences in FLSS and QoL scores between the pilot, immediate, and delayed treatment groups were evaluated using the chi-square test for categorical variables and the Kruskal-Wallis test for continuous variables. The comparisons of change in results from baseline to year 4 and from year 2 to 4 and for the pilot, immediate, and delayed treatment groups and entire group as a whole were anxiety, and depression scores that were measured using validated instruments. 14, 15 However, publication of several cases of delayed adverse events associated with PAIG have called the long-term safety of this product into question. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Most notably, several centers have described infectious complications such as cellulitis and abscess formation following the prolonged use of PAIG for HIV-associated FLA. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Given the ramifi cations of delayed infectious complications on the sustained use of PAIG, we sought to explore the occurrence of such events in a group of treated patients who participated in a randomized controlled trial (RCT). In this report, we present the 4-year follow-up data of the 31 patients enrolled in the open-label RCT, along with 5 patients who were previously enrolled in a pilot study.
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METHODS
Study Population and Design
Details of the study methodology have been previously described.
14 Briefl y, 31 HIV-positive individuals with FLA were enrolled from April to September 2005 and were randomly assigned to receive either immediate (weeks 0 and 6; n = 16) or delayed (weeks 12 and 18; n = 15) PAIG injections administered into the subcutaneous plane using aseptic technique. Additional injections ("touch-ups") were arranged if the treating surgeon deemed the initial level of correction less than optimal. Injection techniques employed in this study were previously described.
14 An additional 5 patients were enrolled in a pilot study in November 2004 prior to launching the full-scale study. 30 All pilot and full-scale study participants had FLA confirmed by physician assessment, were 18 years of age or older, had received no prior corrective therapy for FLA, and provided written informed consent prior to participation in the study. The original study protocol and subsequent amendment for a 4-year follow-up visit were approved by an independent research ethics board.
Assessments
The long-term safety of the PAIG was assessed by asking participants whether they experienced the following complications: pain, swelling, redness, bruising, nodules, bleeding, necrosis, and infection. Infections were classifi ed as "confi rmed" 45 years (IQR, 43-46). At baseline, the 31 patients in the full-scale study had a median physician FLSS of 2 (IQR, 1-3) and 23 (74%) of them had moderate to severe FLA (ie, grade 2-4). All 5 patients in the pilot study had moderate to severe FLA with a median physician FLSS of 4 (IQR, 3-4). The additional baseline characteristics for the participants are summarized in Table 1 . Four participants were lost to follow-up, and subsequent results report on the remaining 32 participants.
Safety
The delayed adverse events through 4 years of follow-up for the pilot and full-scale studies are carried out using the Wilcoxon sign rank test. The satisfaction questions were dichotomized and summarized using proportions for the pilot and full-scale RCT participants separately as well as for the combined group as a whole; comparisons were made using the chi-square test.
RESULTS
Baseline Characteristics
Thirty of the 31 patients enrolled in the full-scale study were male, and the median age of the cohort was 48 years (IQR, 45-55), whereas all 5 patients in the pilot study were male with a median age of Note: Immediate and Delayed treatment groups were part of full-scaled open-labeled randomized study. Values given are n (%), unless otherwise indicated. ART = antiretroviral therapy; d4T = stavudine; ddI = didanosine; IQR = interquartile range. a For more detailed study population demographics, see prior publications. 14, 15, 30 summarized in Table 2A , for the 32 participants with 4-year follow-up. Many adverse events occurred immediately after the injection and were mostly mild and transient, resolving after a median of 3 days (IQR, 2-5), and they are described in earlier publications. 14 The most signifi cant delayed adverse events reported were infections and nodules. There were 5 confi rmed infections (15.6%) with a median time of occurrence of 2.8 years (IQR, 2.5-3.5) from baseline PAIG injection; the duration between onset and resolution was 30 days (IQR, 30-60). Four patients with confi rmed infections had organisms cultured from suctioned material (3 with purulent material and 1 with serous material). Three additional participants described possible infections (9.4%), with a median time of occurrence of 3.7 years (IQR, 1.5-4.4) from baseline PAIG injection and a duration between onset and resolution of 10 days (IQR, 4-30). All participants with confi rmed and possible infections described localized edema, pain, and erythema. Infectionrelated risk factors, precipitating events, and management are detailed in Table 2B . All patients Table 2A . Reported injection-related adverse events from the pilot study and full-scale study Oral antibiotics used included cephalexin in 2 cases; penicillin, clindamycin and cephalexin combined and ciprofl oxacin in 1 case each; and 3 with unspecifi ed antibiotic. Specifi c IV antibiotics were unspecifi ed in all cases. Antibiotics used were selfreported, not confi rmed in chart. c Organisms isolated included Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, and Enterobacter cloacae in 1 case each; 1 case had an unspecifi ed organism. The 3 confi rmed organisms were confi rmed in hospital chart. Table 2B . Continued with confi rmed infections had dental procedures including routine dental cleaning prior to developing an infection, compared to 63% who did not have confi rmed infection (P = .16) ( Table 3) . For the 3 patients with possible infections, 1 had prior dental procedures (33%). In comparison to participants with no infection, those with confi rmed or possible infections had an odds ratio of 1.5 (95% CI, 0.2-9.2; P = .99) for prior dental procedures. The only other covariate associated with infection, both confi rmed and confi rmed/possible, was more severe FLA grade ( Table 3) . Additional delayed complications observed in patients included nodules (n = 8; 25%, all the nodules were ongoing) and bleeding (n = 1; 3%). There were no correlates of nodules (data not shown). There were no cases of necrosis.
Effi cacy
The 4-year effi cacy results of the study are summarized in Table 4 . An analysis for the entire PAIG between years 2 and 4. While there were no signifi cant changes observed in median patientgraded FLSS, MOS-HIV QoL, sDQLS, physical and mental health summary scores, or depression and anxiety scores between years 2 to 4 of follow-up, a signifi cant difference in median physician FLSS score was observed during this time frame (1; IQR, 0-1; P < .001).
MOS-HIV
Satisfaction
The answers to the satisfaction questions separated by group are presented in Table 5 . The proportion of the overall patients responding that they were satisfi ed or very satisfi ed with their overall treatment and treatment with PAIG specifically was 94% and 69%, respectively ( Table 6 ). Seventy-eight percent of patients would recommend treatment with PAIG injections ( Table 6 ).
group as a single cohort was also conducted assessing the change from baseline to year 4, as most effi cacy endpoints showed no difference between the groups. Physician and patient FLSS scores both changed by a median of -2 (IQR, -2, -1) (P < .001) and -1 (-3, -1) (P < .001) from baseline to year 4, respectively. Changes in QoL and physical health domains of the MOS-HIV scale at year 4 relative to baseline were not signifi cantly different. Improvements were observed for the mental health domain (P = .02), sDQLS (P < .001) and in both the depression (P < .001) and anxiety (P < .001) portions of the HADS scale from baseline to year 4.
Because our last follow-up report was at 2 years from baseline, a comparison of outcome measures between years 2 and 4 was performed ( Table 5) . There were 2 patients from the pilot group and 1 patient from the full-scale immediate group who received additional touch-up injections of Table 5 . Changes in facial lipoatrophy severity and quality of life scores from 2 to 4 years We were reassured that effi cacy was in general no different between years 2 to 4 following PAIG injection. Perhaps most importantly, there was no difference in patient-graded FLSS, MOS-HIV QoL, physical and mental health summary scores, and depression and anxiety scores during this interval. We were also reassured to fi nd that 94% of patients were satisfi ed with their overall treatment; however, fewer were satisfi ed with the PAIG specifi cally. Furthermore, 78% of participants stated that they would recommend treatment with PAIG, suggesting that PAIG may still have a role in the treatment of HIV-associated FLA. Our satisfaction results are important to interpret in the context of the history of release and availability of dermal fi llers in Canada. PAIG was the fi rst fi ller available for use of FLA in Canada in 2005 and was welcomed by members of the HIV-positive community who suffered from severe pathologic facial dysmorphias.
Our study has several limitations, some of which have been presented in previous publications. 14, 15 The main limitation for this analysis is the subjective ascertainment and lack of objective defi nition of complications. Defi ning infections objectively posed particular diffi culty. The 2 clinical factors supporting the diagnosis of the 5 identifi ed cases of "confi rmed" infections were the presence of purulent material and the microbiologic confi rmation of an infectious organism. On the other hand, while the "possible" infections clinically presented in a
DISCUSSION
The results of our study provide the fi rst evidence of delayed complications associated with PAIG originating from a controlled clinical trial with suffi cient follow-up for an assessment of the product safety. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] One of our most important fi ndings is the report on delayed adverse events, including confi rmed infections at a rate of 15.6% approximately 2.5 years on average from baseline injection that lasted a total of 30 days. Furthermore, an additional 9.4% of participants described a clinical picture consistent with possible infection. As all the possible infections presented with pain, edema, and erythema, it is possible that they were infl ammatory reactions rather than infections. It is important to note that all cases of infection resolved after the administration of antibiotics (confi rmed and possible), and most required surgical removal of the PAIG (100% for confi rmed infections, 33% for possible infections). Because all the patients who experienced a confi rmed infection did so following dental procedures, clinicians may consider providing antibiotic prophylaxis to patients with PAIG implants prior to dental procedures. The other clinical variable associated with infection was severity of FLA; this would be an important counseling point for patients with grade 3 or 4 FLA considering treatment with PAIG. The other signifi cant delayed complications were nodules and bleeding at rates of 25% and 3%, respectively. similar fashion with erythema, edema, and pain, the lack of the 2 confi rming clinical factors prevented classifi cation of these cases as "confi rmed." Some experts may propose that the possible infections we have reported are cases of infl ammation. From a clinical standpoint, whether caused by infection or infl ammation, the symptoms were considered severe by the patients, lasted for an extended period of time, and were often treated with antibiotics and surgical management. A further limitation is that data on other important complications were not gathered including mitigation and ridging. In summary, while we found that treatment of HIV-associated FLA with PAIG in our study population resulted in long-term sustained physical effi cacy (as defi ned using the physician-and patient-scored FLSS and mental effi cacy using QoL, anxiety and depression instruments), delayed complications were common and severe. The most signifi cant complication was infection occurring in 1 in 7 to 1 in 4 of our population after a median of 2.5 years. This may represent early signs of signifi cant rates of long-term complications in our population. We are concerned that the proportion of patients with infection may increase with time as described by others. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] For this reason, we have decided to continue the follow-up of our study with additional visits at 7 and 10 years after PAIG injection. Also, because all of the "confi rmed" infections occurred following a dental procedure, clinicians may wish to consider providing antibiotic prophylaxis to patients with PAIG implants prior to such procedures. Such antibiotic prophylaxis should cover skin and oral fl ora such as amoxicillin/clavulanic acid or clindamycin. Another consideration would be to use cephalexin or amoxicillin, which are the antibiotics recommended for patients with prosthetic point replacements. 35, 36 This recommendation merits further investigation and discussion.
